arrow
L

Laurent Mineur

Institut Sainte Catherine
H指数:48
被引数:1.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer (GRECCAR 15): superiority open-label phase III randomized clinical trial

化疗联合盆腔再放疗与单独化疗作为局部复发直肠癌术前治疗的优效性开放标签III期随机临床试验 (GRECCAR 15)

bjs
IF0
2026-05-130
PRE
Deep learning on histological slides accurately predicts Consensus Molecular Subtypes and spatial heterogeneity in colon cancer

基于组织学切片的深度学习能够准确预测结直肠癌的共识分子亚型及空间异质性

2025-08-250
PRE
Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (PRODIGE 62-FFCD 1701-OESIRI)

Nal-IRI/LV5-FU 与紫杉醇作为转移性食管鳞状细胞癌患者二线治疗的比较(PRODIGE 62-FFCD 1701-OESIRI)

2025-08-220
OAAI
Impact of concomitant medication on recurrence, survival and tolerability of chemotherapy in early colon cancer patients – A post-hoc analysis of the PETACC 8 trial

合并用药对早期结直肠癌患者复发、生存和化疗耐受性的影响——PETACC 8试验的事后分析

2025-07-120
OA
Regorafenib plus modified gemcitabine-oxaliplatin in patients with advanced biliary tract cancer. The randomized phase Ib/II BREGO study

瑞戈非尼联合改良吉西他滨-奥沙利铂方案治疗晚期胆道癌。BREGO研究(随机 Ib/II 期)。

2025-06-010
OAAI
Bevacizumab-based chemotherapy adaptive to pharmacokinetic of bevacizumab in first-line treatment of patients with unresectable metastatic colorectal cancer: A double-blind, multicenter, randomized phase III trial study (PHARBEVACOL trial)

基于贝伐珠单抗的化疗,根据贝伐珠单抗药代动力学适应性调整,用于不可切除性转移性结直肠癌患者的一线治疗:一项双盲、多中心、随机III期临床试验研究(PHARBEVACOL试验)

2025-05-010
OAAI
A phase III randomised trial on the addition of a contact X-ray brachytherapy boost to standard neoadjuvant chemo-radiotherapy for organ preservation in early rectal adenocarcinoma: 5 year results of the OPERA trial

一项关于在早期直肠腺癌器官保留中,将接触式X射线近距离治疗推量添加到标准新辅助化放疗的III期随机试验:OPERA试验的5年结果

2025-02-015
PRE
Induction triplet chemotherapy in patients with rectal adenocarcinoma and synchronous metastases, an AGEO-FFCD study

直肠腺癌伴同步转移患者的诱导三联化疗:一项AGEO-FFCD研究

2025-01-010
OAAI
Phase I/II study of trifluridine/tipiracil plus XB2001 versus trifluridine/tipiracil in metastatic colorectal cancer
2024-11-121
OA
Final Results of the GRECCAR-6 Trial on Waiting Period Following Neoadjuvant Radiochemotherapy for Locally Advanced Rectal Cancer: 5 Years of Follow-up
2024-11-070
PRE
A randomized phase III trial of perioperative chemotherapy (periop CT) with or without preoperative chemoradiotherapy (preop CRT) for resectable gastric cancer (AGITG TOPGEAR): Final results from an intergroup trial of AGITG, TROG, EORTC and CCTG

一项随机III期临床试验,研究围手术期化疗(periop CT)联合或不联合术前化放疗(preop CRT)对可切除胃癌(AGITG TOPGEAR)的治疗效果:来自AGITG、TROG、EORTC和CCTG协作组试验的最终结果

2024-09-011
PRE
Tolerance of adjuvant chemotherapy in older patients after resection of stage III colon adenocarcinoma from PRODIGE 34-FFCD 1402-ADAGE randomized phase III trial

PRODIGE 34-FFCD 1402-ADAGE 随机III期试验中,III期结肠腺癌切除术后老年患者辅助化疗的耐受性

2024-09-010
PRE
Time to recurrence and its relation to survival after recurrence in patients resected for stage III colon cancer

III期结肠癌切除患者的复发时间及其与复发后生存的关系

2023-11-014
OAAI
Preliminary tolerance analysis of adjuvant chemotherapy in older patients after resection of stage III colon cancer from the PRODIGE 34-FFCD randomized trial
2023-04-019
OAAI
TACE and conformal radiotherapy vs. TACE alone for hepatocellular carcinoma: A randomised controlled trial
2023-04-013
OAAI